Related references
Note: Only part of the references are listed.Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment
Jing Li et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Alexander Ou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Quantification of abemaciclib and metabolites: evolution of bioanalytical methods supporting a novel oncolytic agent
Enaksha R. Wickremsinhe et al.
BIOANALYSIS (2021)
Molecular Mechanisms of Drug Resistance in Glioblastoma
Maya A. Dymova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Current Development of Glioblastoma Therapeutic Agents
Zilai Wang et al.
MOLECULAR CANCER THERAPEUTICS (2021)
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Shripad V. Bhagwat et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Simultaneous quantification of abemaciclib and letrozole in rat plasma: method development, validation and pharmacokinetic application
Pooja Dhakne et al.
BIOMEDICAL CHROMATOGRAPHY (2020)
Novel Therapies for Glioblastoma
Elisa K. Liu et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2020)
Glioblastoma multiforme: novel therapeutic targets
Matthew Muir et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments
Vilashini Rajaratnam et al.
CANCERS (2020)
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2020)
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2020)
Management of glioblastoma: State of the art and future directions
Aaron C. Tan et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
Alejandra Martinez-Chavez et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2019)
Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery
Travis T. Wager et al.
ACS CHEMICAL NEUROSCIENCE (2016)
The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6
Teresa Burke et al.
CANCER RESEARCH (2016)
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Thomas J. Raub et al.
DRUG METABOLISM AND DISPOSITION (2015)
Share Paper
